ActiveMSers Forums  

Go Back   ActiveMSers Forums > ActiveMSers.org Forums > General

Reply
 
Thread Tools Display Modes
  #1  
Old 07-22-2017, 05:26 PM
Suebee Suebee is offline
MS Gladiator
 
Join Date: Mar 2015
Location: Houston, TX
Posts: 404
Default Just a peek into insurance/marketing of Ocrevus

From AIS.com May 2017:
" Ocrevus (ocrelizumab) for primary progressive multiple sclerosis (PPMS) and relapsing MS (RMS), approved March 29: The infusible from Genentech USA, Inc., a Roche Group company, is the only treatment the FDA has approved for PPMS, which is diagnosed in about 15% of people with MS, says Kunze. “It will likely be approved for primary progressive MS without much pushback from plans,” she says. People with PPMS “technically shouldn’t be getting treated because nothing is approved for that indication. We assume this is an untreated population, but we know current therapies are being used off label,…but we don’t know to what extent,” since ICD-9 and ICD-10 codes just indicate a diagnosis of MS.

However, Kunze says, Ocrevus’ use in RMS will be “an interesting battle” in that it’s “priced pretty competitively to” other self-injected therapies that treat the condition: $65,000 annually.


from : https://aishealth.com/archive/nspn0417-01
Reply With Quote
Reply

Tags
access, multiple sclerosis, ocrevus, prescriptions, price

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 10:26 PM.


Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.
ActiveMSers